Andrew Storey has over 30 years in the biopharmaceutical industry providing leadership for Regulatory Affairs. He is presently Vice President, Global Regulatory Strategy for AbbVie and was a VP with global responsibilities for the previous 14 years at Cangene. Prior to that he held several regulatory positions in small biotech companies. He has also had VP responsibilities for Clinical Research, Medical Affairs, Quality Assurance and Quality Control in addition to his Regulatory Responsibilities. He has led the development of many innovative products and therapies and also successfully licensed a biosimilar product in the US in 2008. Post 9/11, he spent 11 years working on the development of Medical Countermeasures to Bioterrorism and worked with CDC, NIH and BARDA to install multiple biodefense products into the US Strategic National Stockpile (SNS) as well as in other global stockpiles. He has worked on Orphan drugs and indications throughout his career. He is presently applying his expertise to exciting challenges at AbbVie related to the Humira/Immunology and HCV franchises, as well as a comprehensive pipeline of Oncology products at AbbVie.